33 results about "Organ damage" patented technology

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

This invention relates to the field of biomedical technology and discloses an amphiphilic nicotinamide adenine dinucleotide (NAD) + Couplings, nanomicelles and their applications. Amphiphilic NAD+ + Couplings have the following general structural formula: ; where NAD + R is a hydrophilic group, R is a hydrophobic antioxidant group, and phenylboronic acid derivative is the linking bond; R is selected from free radical scavengers, small molecule organoselenic compounds that mimic the function of glutathione peroxidase 4, iron chelating agents, 7-dehydrocholesterol, royal jelly acid, α-lipoic acid, oleic acid, or derivatives of the above molecules. In this invention, NAD... + Conjugates and their self-assembled nanomicelles possess functions such as promoting DNA repair, maintaining cellular homeostasis, and delaying aging. Simultaneously, nanomicelles can inhibit inflammation and oxidative stress, and can physically encapsulate hydrophobic active drugs, showing broad application prospects in inflammatory diseases, age-related diseases, organ damage, and the prevention and treatment of toxic side effects from chemotherapy drugs.

The application discloses a bat moth lepidoptera cordyceps strain and application thereof in preparation of anti-neutron radiation medicines. Samsoniella hepiali The strain is the bat moth lepidoptera cordyceps strain P969 (Pleurotus spodoleucus), which is preserved in the China Center for Type Culture Collection and has a preservation number of CCTCC NO: M 20251172 and a preservation date of May 26, 2025. Mycelium extracts of the strain can protect biological tissues against neutron radiation and repair organ damage caused by neutron radiation, so that the strain has a wide development space and a good development and application prospect.

The application belongs to the technical field of biological medicine, and relates to a mussel peptide and a preparation method and application thereof. The mussel peptide comprises one or more of the following peptide segments: (1) Ile-Leu-Thr-Glu-Arg (2) Leu-Asp-Leu-Ala-Gly-Arg (3) Val-Thr-Ile-Met-Pro-Lys (4) Met-Gln-Ile-Phe-Val-Lys (5) Leu-Phe-Asp-Ala-Val-Ile-Arg. The mussel peptide is prepared by adopting a complex enzyme-membrane separation-dextran gel column chromatography purification coupling technology. The peptide not only has the effect of relieving spontaneous hypertension, but also has the effect of improving various target organ damages caused by spontaneous hypertension. The application provides the possibility of application of the mussel peptide in improving various target organ damages caused by spontaneous hypertension or other diseases.

The utility model relates to bulletproof apron technical field, concretely refers to a multifunctional bulletproof apron. Including front apron and back apron, the front apron includes tactical waist seal, and the both sides of tactical waist seal all have elastic waistband, and the top side of tactical waist seal has two quick -release insert buckles no. 1, and the bottom side of tactical waist seal has two pieces of side leg guard, the chaff guard, two pieces of front leg guard, the back apron includes the protective outer seat pad and the protective inner seat pad of upper and lower layer structure, and the protective inner seat pad has adjustable waistband, and the both ends of adjustable waistband are connected through quick -release insert buckle no. 2, the bulletproof apron is composed of inner fabric layer, outer fabric layer and protective layer, and inner fabric layer and outer fabric layer suture and wrap protective layer. The utility model provides a kind of multifunctional bulletproof apron with bulletproof, anti-fragment, anti-knife cone, high temperature resistance, infrared radiation and comfort, can comprehensively protect the key parts below waist, reduce reproductive organ damage, and do not affect tactical action, improve combat survivability.

This invention discloses a novel copper death inhibitor and its application in the preparation of drugs for treating sepsis, belonging to the fields of pharmaceutical formulation and biomedicine. This invention discloses a method for preparing a novel copper death inhibitor, which can be used to develop highly efficient and low-toxicity copper death inhibitors. This agent can be used to prepare drugs for preventing sepsis-related organ damage and is a potential treatment for sepsis. It can inhibit copper death in sepsis-induced lung, kidney, liver, and cardiomyopathy, and reduce inflammatory responses and organ damage. Furthermore, this invention has the outstanding advantages of high specificity, high bioavailability, significant efficacy, and a stable preparation method, showing broad application prospects.

This invention discloses an injectable AuPd-Fe single-atom nanozyme composite drug-derived antibacterial hydrogel, its preparation method, and its applications, belonging to the field of biomedical nanomaterials technology. This invention uses an iron-based single-atom nanozyme with an irregular octahedral carbon framework structure as the core catalytic carrier, and in situ loads ultra-small AuPd alloy nanoparticles onto its surface to obtain the AuPd-Fe single-atom nanozyme. Then, using the AuPd-Fe single-atom nanozyme as the active center and oleanolic acid drug-derived hydrogel as the delivery carrier, the AuPd-Fe single-atom nanozyme is uniformly dispersed in the three-dimensional network of the OA hydrogel through physical embedding and hydrogen bonding, resulting in the injectable AuPd-Fe single-atom nanozyme composite drug-derived antibacterial hydrogel. The provided antibacterial hydrogel exhibits excellent ocular surface biocompatibility, no significant corneal toxicity, and no systemic organ damage. It also shows significant clinical application potential for blinding ocular infections such as drug-resistant bacterial keratitis and corneal ulcers.

This invention discloses a traditional Chinese medicine composition for improving fever due to wind-cold and its application, belonging to the field of traditional Chinese medicine technology. Targeting the core pathogenesis of fever due to exogenous wind-cold, this invention combines modern thermoregulation and microcirculation pathological mechanisms, based on the principle of hypothalamic preoptic thermoregulatory center regulation. It abandons the drawbacks of Western medicine ibuprofen, which forcibly intervenes in the hypothalamic thermoregulatory center, constricts visceral blood vessels, and aggravates organ damage. It overcomes the technical defects of traditional Chinese medicine, which simply induces sweating to relieve exterior symptoms, depletes qi and damages yang, and easily leads to recurrence. The formula uses ephedra, curculigo, angelica pubescens, and galangal in combination. Through the synergistic effects of dispersing cold and clearing the lungs, warming yang and consolidating the collaterals, warming the middle jiao and dispelling pathogens, and unblocking the meridians, it gently regulates the homeostasis of the hypothalamic thermoregulatory center, expands spasmodic capillaries on the body surface and in the internal organs, improves the body's microcirculation, dispels cold pathogens from the skin surface, warms and unblocks the blood vessels of the internal organs, and also protects the heart, liver, and kidneys, strengthening the body's foundation and nourishing the vital energy. This achieves a comprehensive improvement of fever due to wind-cold, with mild medicinal properties, stable efficacy, and no risk of organ damage.

The present disclosure provides improved methods for reprogramming and gene editing cells. In one aspect, the present disclosure provides a method of introducing a single strand break in a DNA site. In one aspect, the present disclosure provides a method of inserting a sequence in a DNA site by introducing a single strand break followed by insertion of the sequence using a single-stranded repair template. In another aspect, the present disclosure provides a method of activating gene expression in a cell during its differentiation. In another aspect, the present disclosure methods and compositions related to iPSC-derived mesenchymal stroma / stem cells that overexpressed IDO1. In another aspect, the present disclosure provides a solid support comprising iPSC-derived mesenchymal stem cells which can be used to treat organ damage.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

This invention discloses a water-oil dual-phase synergistic anti-fibrotic comprehensive formulation framework and its application based on Camellia chrysantha and Aristolochia debilis, belonging to the field of ethnic Zhuang medicine biomedicine and herbal chronic disease management technology. This invention is the first to fix Camellia chrysantha and Aristolochia debilis as the unique dual-core framework, creating a novel dual-phase synergistic underlying pharmacology of water-phase flavonoids against organ fibrosis and oil-phase α-linolenic acid for anti-inflammatory and plaque-stabilizing effects. It constructs a three-tiered comprehensive application system covering daily health maintenance, organ damage repair, early-stage fibrosis, and blocking of high-risk vascular lesions. This system can be extended to adapt to various chronic disease herbal compositions and industrial applications in multiple dosage forms such as tea, granules, and capsules. This invention is highly original, has a closed-loop pharmacological logic, and is highly applicable, filling the gap in existing technologies for fixed dual-core formulations and water-oil dual-phase comprehensive conditioning frameworks. It possesses extremely high scientific research value, intellectual property barriers, and industrial application value.

This invention discloses the application of ZAK inhibitors in the preparation of drugs for treating EV71 virus infection, relating to the biomedical field. The ZAK inhibitors exert their effects by inhibiting the ZAK-p38 MAPK signaling pathway and by inhibiting the ZAKα-mediated ribosomal toxicity stress response (RSR). The ZAK inhibitor is nilotinib or a pharmaceutically acceptable salt thereof. Cellular and animal experiments of this invention demonstrate that EV71 infection activates the ZAKα-mediated p38 MAPK pathway (RSR), promoting viral replication and leading to multi-organ damage. ZAK inhibitors (such as nilotinib) can inhibit this pathway, reduce the expression of the viral protein VP1, and improve infection-induced renal function damage, metabolic disorders, and muscle damage. Therefore, ZAK inhibitors can be used to prepare anti-EV71 drugs.

This invention discloses the application of PGLYRP1 in the diagnosis and treatment of sepsis, belonging to the technical field of sepsis treatment and prognosis. The application of PGLYRP1 inhibitors in the preparation of drugs that enhance the body's bacterial clearance capacity and reduce apoptosis in multiple organs is characterized by the inhibitor exerting its therapeutic effect by reducing bacterial load in blood, peritoneal lavage fluid, and spleen; the PGLYRP1 inhibitor is used to antagonize the bacterial clearance inhibition effect mediated by elevated PGLYRP1 levels. This invention reveals that the expression of the novel immunomodulatory factor PGLYRP1 is significantly increased in sepsis patients, and its expression level is significantly positively correlated with poor prognosis of sepsis. Using a CLP-induced sepsis mouse model, this invention found that the expression level of PGLYRP1 in the blood and peritoneal lavage fluid (PLF) of sepsis mice was significantly increased. Treatment with recombinant protein PGLYRP1 significantly increased bacterial load and exacerbated multi-organ damage in septic mice, thereby significantly reducing their survival rate. Conversely, treatment with PGLYRP1 neutralizing antibody significantly reduced bacterial load and alleviated multi-organ damage in septic mice, thereby significantly improving their survival rate.

This invention relates to the field of surgical instruments, and more particularly to a minimally invasive organ suspension device that expands surgical space. The organ suspension device includes an external magnetic suspension device and an internal detachable clamp; the magnetic suspension device includes a strong magnetic system (15), and an mounting rod sleeve (14) is arranged above the strong magnetic system (15); the detachable clamp includes a dedicated internal arc-shaped clamp body (1). This invention's minimally invasive organ suspension device uses external magnetic attraction in conjunction with an internal detachable clamp to achieve minimally invasive organ suspension, minimizing tissue traction trauma during surgery and reducing postoperative complications. It eliminates the need for suturing organs and external punctures, avoiding organ damage and the risk of infection at puncture wounds.

This invention discloses a traditional Chinese medicine composition for treating various cancers and its preparation process, belonging to the field of natural Chinese medicine anti-tumor technology. It aims to address the technical shortcomings and industry gaps of existing anti-cancer Chinese medicines, such as significant toxic side effects, limited intervention scenarios, lack of standardized medication systems, complex processes, and poor recurrence prevention. The composition of this invention consists of ten pure natural and non-toxic raw materials, including Ligusticum chuanxiong, Curcuma zedoaria, and red clover powder. The total weight of a single dose is fixed at 33g, with consistent compatibility requiring no adjustments based on syndrome differentiation. It eliminates toxic medicinal materials and chemical excipients, making it suitable for all solid cancers except leukemia. This invention features a unique three-stage standardized intervention program. This invention can inhibit cancer cell proliferation and metastasis at multiple targets, effectively prevent tumor recurrence, and simultaneously repair the body's immune system and organ damage. It exhibits no drug resistance or cumulative toxicity, possessing advantages such as safety, long-lasting efficacy, broad-spectrum compatibility, standardization, and easy mass production. It effectively fills the gap in pure natural prevention and control technology for the entire cycle of solid cancer, and has extremely high clinical application value.

This invention discloses a traditional Chinese medicine composition for treating cerebrovascular diseases, belonging to the technical field of cerebrovascular disease drugs. The composition comprises the following components in parts by weight: 10-30 parts of Polygonatum sibiricum, 6-15 parts of Rosa laevigata, 6-12 parts of Euonymus alatus, 6-15 parts of Polygonum cuspidatum, 3-9 parts of Acorus tatarinowii, 3-10 parts of Alpinia oxyphylla, 3-6 parts of Aralia elata septum, 3-10 parts of Rhodiola rosea, 3-10 parts of Bletilla striata, and 1-6 parts of Cinnamomum cassia. This invention addresses the pathological characteristics of cerebrovascular diseases, including long disease courses, multiple risk factors, and involvement of multiple target organs. Through the systematic combination of ten herbs, it can simultaneously achieve cerebrovascular protection, nerve function repair, and protection against multi-organ damage. Animal experiments and clinical observations have confirmed that this composition can significantly improve patients' neurological deficit scores, reduce the incidence of complications, and has clear preventive and therapeutic effects on secondary complications such as stress ulcers and renal impairment, while also possessing antithrombotic and hemostatic properties and high safety.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.

This invention discloses a 3D scaffold for repairing defective lung injury, its construction method, and its applications, belonging to the field of biomedical materials and tissue engineering technology. This invention uses cationic polysaccharide chitosan and polymer γ-polyglutamic acid as raw materials, utilizing their electrostatic interaction to achieve cross-linking without cross-linking agents, and combines this with freeze-drying technology to prepare a three-dimensional spherical γ-PGA / CS composite scaffold. The above composite scaffold is combined with bone marrow stem cell exosomes (MSC-Exos) and type II alveolar epithelial cells (RLE-6TN). By loading exosomes onto the scaffold and implanting lung cells, local enrichment and targeted delivery are achieved, solving the problems of poor targeting of bone marrow stem cell exosomes and easy loss during transplantation of individual cells. This functional scaffold can accelerate lung function recovery by regulating the inflammatory microenvironment at the site of lung injury in SD rats, promoting lung cell regeneration, and reducing secondary lung tissue damage. It provides a novel implantable, minimally invasive treatment for defective lung injury-related diseases, possessing good clinical translational potential and application prospects in organ damage repair.

The application discloses a nerve ablation control system based on a pulse electric field. A construction module in the system is used to construct a target ablation model, a determination module calculates nerve activity indexes according to electrophysiological signals of each mapping site, and determines each target active target point based on the nerve activity indexes, an ablation module performs nerve ablation on the target active target point according to the pipe wall thickness, and a judgment module executes a nerve ablation end instruction when all the target active target points meet preset ablation conditions after nerve ablation. Through the above nerve ablation control system, targeted nerve ablation is realized on each target active target point based on the calculated nerve activity indexes, and a self-adaptive pulse voltage is adopted according to the pipe wall thickness, so that organ damage caused by blind ablation or invalid ablation caused by too low pulse voltage amplitude is avoided, the requirement of high-precision ablation is met, and the use satisfaction of the ablation system is improved.

The application discloses application of Ms4a1 in peripheral blood leukocytes in calculation of high-energy neutron radiation dose, and relates to the technical field of biological detection. The application focuses on the biological effect and damage mechanism of neutron radiation, and potential biomarkers under dose gradient are screened. The LD50 and LD100 of mice under neutron radiation are determined as 8 Gy and 12 Gy respectively. The damage degree of radiation-sensitive organs such as spleen and intestinal tract is aggravated with dose gradient. The number of lymphocytes in the blood system is significantly reduced with dose, and can be used as an evaluation index of radiation damage. Cytokines such as IL-6 and IL-10 are significantly up-regulated, which indicates the inflammation and immune regulation mechanism. Ms4a1 is finally screened as a potential key gene, and the expression amount of Ms4a1 changes significantly before and after irradiation, and has very high sensitivity. The method can realize rapid and objective estimation of the neutron radiation dose by detecting the expression amount of Ms4a1 in peripheral blood leukocytes and substituting the dose-effect function, and has clinical transformation value.

Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.

This article discloses methods for local expression and administration of RNA molecules at sites of acute inflammation, methods for treating tissue or organ damage in subjects characterized by sites of acute inflammation in tissues or organs, methods for treating subjects with sites of acute inflammation in tissues or organs, methods for treating tissue damage in the heart or brain in subjects caused by local ischemia, and medical products or kits suitable for administration and local expression at sites of acute inflammation.

A self-powered electrocatalytic alcohol solution capsule and a preparation method and application thereof, the alcohol solution capsule comprising a shell, an encapsulation layer arranged in the shell, and an electrochemical unit coated with the encapsulation layer, the electrochemical unit comprising a catalytic electrode, a counter electrode, and an electrolyte layer between the catalytic electrode and the counter electrode, the catalytic electrode comprising a gold foil and a manganese-tannic acid mesocrystal, wherein the manganese-tannic acid mesocrystal is a mesoscopic crystal structure formed by self-assembly of a metal-polyphenol network of a tannic acid and a manganese salt under weak acid conditions on the gold foil. The alcohol solution capsule of the present application adopts a self-generating primary cell structure assembled by edible catalytic electrodes, counter electrodes, electrolyte layers, encapsulation layers, and shells, can efficiently oxidize ethanol in situ in the intestinal tract through electrochemistry, and convert the ethanol into acetic acid, so as to achieve active removal before the ethanol is absorbed into the blood in a large amount, and achieve the purposes of reducing the blood alcohol concentration, reducing alcohol-related organ damage, and improving neurobehavioral impairment.

The application discloses a kind of alpha-lipoic acid loaded polylactic acid composite nanoparticles and preparation method and application thereof.The nanoparticles are formed with polylactic acid-glycolic acid copolymer to form a hydrophobic inner core, with distearoyl phosphatidyl ethanolamine-polyethylene glycol- triphenylphosphine to form a surface functional layer, and alpha-lipoic acid is loaded. The system has the advantages of mild preparation conditions, uniform particles, high drug loading efficiency, slow release in gastric acid environment, sustained release in neutral or weak acid environment, good cell compatibility, and enhanced mitochondrial regional positioning. The nanoparticles can reduce hypoxia-induced reactive oxygen species and Ca²⁺ elevation, improve ATP deficiency, and reduce myocardial and lung tissue damage, and are suitable for preparing pharmaceutical preparations for alleviating hypoxia-induced mitochondrial dysfunction and related organ damage.

This invention relates to a fixation device for an indwelling catheter used in intraperitoneal hyperthermic perfusion, comprising a fixing block, a first fixing part, a second fixing part, a shaft, a blade, and a baffle. The fixing block has a through hole connecting its upper and lower sides. The upper side of the fixing block is recessed downwards to form an arc-shaped groove for accommodating the upper part of the indwelling catheter and a connecting groove. The center of the arc-shaped groove is located on the axis of the through hole. One end of the connecting groove is connected to one end of the arc-shaped groove, and the other end is connected to the upper end of the through hole. When the upper end of the indwelling catheter is pulled upwards, the wall of the indwelling catheter pushes the baffle to rotate. The baffle drives the shaft and the blade to rotate, and the blade's cutting edge rotates towards the through hole and sweeps across the location of the through hole. Due to the adoption of the above technical solution, this invention can reduce the possibility of abdominal puncture site tearing, bleeding, and organ damage when patients attempt to remove the catheter unplannedly and forcefully.

This invention discloses the application of Ikzf3 in peripheral blood leukocytes in calculating high-energy neutron radiation dose, belonging to the field of biodetection technology. This invention focuses on the biological effects and damage mechanisms of neutron radiation, screening potential biomarkers under dose gradients. The LD50 and LD100 of neutron radiation in mice were determined to be 8 Gy and 12 Gy, respectively. The degree of damage to radiation-sensitive organs such as the spleen and intestines increased with the dose gradient. The number of lymphocytes in the blood system decreased significantly with dose, which can serve as an indicator for assessing radiation damage. Cytokines such as IL-6 and IL-10 were significantly upregulated, suggesting inflammatory and immune regulatory mechanisms. Finally, Ikzf3 was screened as a potential key gene, and its expression level changed significantly before and after irradiation, exhibiting extremely high sensitivity. This method, by detecting the expression level of Ikzf3 in peripheral blood leukocytes and substituting it into a dose-response function, can achieve rapid and objective estimation of neutron radiation dose, possessing clinical translational value.

This invention relates to the field of biomedicine, specifically to the application of indolelacic acid in the prevention and treatment of multi-organ damage caused by sepsis. This invention utilizes indolelacic acid to prevent and treat sepsis and its multi-organ damage. In vivo experiments have demonstrated that indolelacic acid can significantly reduce multi-organ damage caused by sepsis, improve survival rates, and has remarkable effects; it also provides a reference for further research on the application of indolelacic acid in the preparation of drugs for systemic inflammatory storms and multi-organ damage caused by sepsis.

The utility model belongs to the field of preventing poisoning, especially a detection mechanism and prevent the device that poisons, the current device cannot be in the automatic and rapid when exceeding standard and accurately show the anti -poisoning mask to the personnel available position, the harmful gas directly invades respiratory tract and causes poisoning, organ damage and other irreversible damage problem, present the following scheme, it includes the box and the anti -poisoning mask, the top of box is set up and opens the passageway, and the inner wall both sides of passageway are slidably provided with the same cover plate, the box is provided with the protection assembly for the personnel and timely obtains the anti -poisoning mask when the harmful gas exceeds standard. The utility model discloses through the setting of protection assembly, realized the automatic and rapid show the anti -poisoning mask when the harmful gas exceeds standard, makes the personnel can obtain the protection in time, effectively avoids the harmful gas direct harm to the human body, greatly reduces the poisoning risk, guarantees the personnel health safety, strengthens the practicality and adaptability of the response to the sudden harmful gas environment.

The application discloses a special device for abdominal cavity opening suture, and belongs to the technical field of medical instruments. The device aims to solve the problems of traditional suture instruments, such as difficult closure of the inner incision, risk of mis-suture of adjacent organs, lack of real-time tension feedback and visual guidance function, and the like, in patients with thick subcutaneous fat tissue due to the limited depth of entry. The device comprises a guide sheath, a puncture execution mechanism and a tissue clamping assembly. The device realizes non-axial puncture through the deflection outlet and the arc transition section, the tissue clamping assembly clamps the inner incision edge, and the double-line loop suture structure enhances the gripping force, so that accurate operation can be guided and ensured and organ damage can be avoided. The suture device can effectively improve the accuracy, safety and standardization degree of abdominal wall suture of patients with thick fat layer, and reduce the risk of postoperative complications.